22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS).
Astrazeneca
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
Pfizer
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
The University of Queensland
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
The University of Queensland
The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure.
Glaxosmithkline
Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D
National Institute of Health Sciences
Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design.
National Institute of Health Sciences
A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors.
Glaxosmithkline
Novel amide and imidazole compounds as potent hematopoietic prostaglandin D
Cayman Chemical
Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer.
National Institute of Health Sciences
The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.
Glaxosmithkline
Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies.
Riken Center For Biosystems Dynamics Research
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity.
Upr 9023
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.
University of Maryland